1. Frantz S. Drug discovery: playing dirty. Nature 2005;437:942-943. PMID:
16222266.
2. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997;6:10-18. PMID:
9394870.
3. Shelton RC. The dual-action hypothesis: does pharmacology matter? J Clin Psychiatry 2004;65(suppl 17):5-10. PMID:
15600376.
4. Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol 2007;555:30-36. PMID:
17109850.
5. Richelson E. Pharmacology of antidepressants. Mayo Clin Proc 2001;76:511-527. PMID:
11357798.
6. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007;68:1195-1205. PMID:
17854243.
7. Paul IA. Excitatory amino acid signaling, major depression, and the action of antidepressants. Pharm News 2001;8:33-44.
8. Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, et al. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol Neurobiol 2006;26:857-873. PMID:
16636898.
9. Randrup A, Munkvad J, Fog R, Gerlach J, Molander L, Kjellberg B, et al. In: Essman WB, Valzelli LMania, depression and brain dopamine. , editor. Current Developments in Psychopharmacology. 1975,vol 2. New York: Spectrum Publications, p. 206-248.
10. D'Aquilla PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405:365-373. PMID:
11033341.
11. Willner P. In: Watson SDopaminergic mechanisms in depression and mania. , editor. Psychopharmacology: The Fourth Generation of Progress. 2000,New York: Lippincott Williams & Wilkins.
12. Skolnick P. In: Schmidt WDopamine and depression. , editor. Dopamine and Glutamate in Psychiatric Disorders. 2005,Totowa: Humana Press, p. 199-214.
13. Axelrod J, Whitby LG, Hertting G. Effects of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science 1961;133:383-384. PMID:
13685337.
14. Young SN, Smith SE, Pihl RO, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 1985;87:173-177. PMID:
3931142.
15. Delgado PL, Miller HL, Salomon RM, Licinio J, Heninger GR, Gelenberg AJ, et al. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol Bull 1993;29:389-396. PMID:
8121966.
16. Delgado PL. How antidepressants help depression: mechanisms of action and clinical response. J Clin Psychiatry 2004;65(Suppl 4):25-30. PMID:
15046538.
17. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, et al. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev 2006;12:123-134. PMID:
16958986.
18. Naranjo CA, Tremblay LK, Busto UE. The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:781-823. PMID:
11383978.
19. Wilkes S. Bupropion. Drugs Today (Barc) 2006;42:671-681. PMID:
17136226.
20. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006;59:203-210. PMID:
16165100.
21. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 18):4-11. PMID:
11575733.
22. Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145. PMID:
9164423.
23. Gwirtsman HE, Szuba MP, Toren L, Feist M. The antidepressant response to tricyclics in major depressives is accelerated with adjuctive use of methylphenidate. Psychopharmacol Bull 1994;30:157-164. PMID:
7831449.
24. Wharton RN, Perel JM, Dayton PG, Malitz S. A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;127:1619-1625. PMID:
4998422.
25. Drimmer EJ, Gitlin MJ, Gwirtsman HE. Desipramine and methylphenidate combination treatment for depression: case report. Am J Psychiatry 1983;14:241-242. PMID:
6849446.
26. Feigner JP, Herbstein J, Damlouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985;46:206-209. PMID:
3997787.
27. Fawcett J, Kravitz HM, Zejecka JM, Schaff MR. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132. PMID:
2056139.
28. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Mehyphenidate augmentation of selective serotonin reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76. PMID:
8591972.
29. Masand PS, Anand VS, Tanquary JF. Psychostimulant augmentation of second generation antidepressants: a case series. Depress Anxiety 1998;7:89-91. PMID:
9614599.
30. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996;40:151-153. PMID:
8793048.
31. Izumi T, Inoue T, Kitagawa N, Nishi N, Shimanaka S, Takahashi Y, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. J Affect Disord 2000;61:127-132. PMID:
11099751.
32. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458. PMID:
7559370.
33. Shelton CI. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful? J Clin Psychiatry 2004;65(Suppl 17):29-33. PMID:
15600379.
34. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-877. PMID:
11775046.
35. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241. PMID:
11230034.
36. Papkostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are anti-depressant drugs that combine serotonergic and noradrenergic mechanisms more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-1227. PMID:
17588546.
37. Nemroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008;63:424-434. PMID:
17888885.
38. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a metaanalyis. J Psychiatry Neurosci 2006;31:122-131. PMID:
16575428.
39. Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006;21:105-110. PMID:
16421462.
40. Roggen H, Kehler J, Stensbol TB, Hansen T. Synthesis of enantiomerically pure milnacepran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. Bioorg Med Chem Lett 2007;17:2834-2837. PMID:
17350257.
41. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci 2003;73:3175-3179. PMID:
14561522.
42. Shuto S, Ono S, Imoto H, Yoshii K, Matsuda A. Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S, 2R)-1-phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker. J Med Chem 1998;41:3507-3514. PMID:
9719604.
43. Kazuta Y, Tsujita R, Ogawa K, Hokonohara T, Yamashita K, Morino K, et al. Synthesis of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) derivatives modified at the carbamoyl moiety as a new class of NMDA receptor antagonists. Bioorg Med Chem 2002;10:1777-1791. PMID:
11937336.
44. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol 2003;461:99-104. PMID:
12586204.
45. Beer B, Stark J, Krieter P, Czobar P, Beer G, Lippa A, et al. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J Clin Pharmacol 2004;44:1360-1367. PMID:
15545306.
46. Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, et al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J Pharmacol Exp Ther 2007;321:1208-1225. PMID:
17325229.
47. Czéh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001;98:12796-12801. PMID:
11675510.
48. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol 2007;555:115-121. PMID:
17112503.
49. McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat. Alcohol Clin Exp Res 2007;31:1866-1871. PMID:
17908267.
50. Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS2330 (tesofensine) in early Parkinson's disease. Mov Disord 2007;22:359-365. PMID:
17149725.
51. Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs 2001;2:1592-1594.
52. Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother 2002;36:225-230. PMID:
11847938.
54. Kiortsis DN, Tsouli S, Fillipatos TD, Konitsiotis S, Elisaf MS. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomized study. Nutr Metab Cardiovasc Dis 2008;18:207-210. PMID:
17570651.
55. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptoms syndromes. J Fam Pract 1999;48:980-990. PMID:
10628579.
56. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007;8(Suppl 2):S63-S74. PMID:
17714117.
57. Koyanagi S, Himukashi S, Mukaida K, Shichino T, Fukuda K. Dopamine D2-like receptor in the nucleus accumbens is involved in the antinociceptive effect of nitrous oxide. Anesth Analg 2008;106:1904-1909. PMID:
18499630.
58. Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(Suppl 4):5-10. PMID:
15046536.